Vis enkel innførsel

dc.contributor.authorRichardsen, Elin
dc.contributor.authorAndersen, Sigve
dc.contributor.authorMelbø-Jørgensen, Christian
dc.contributor.authorRakaee, Mehrdad
dc.contributor.authorNess, Nora
dc.contributor.authorAl-Saad, Samer
dc.contributor.authorNordby, Yngve
dc.contributor.authorPedersen, Mona Irene
dc.contributor.authorDønnem, Tom
dc.contributor.authorBremnes, Roy M.
dc.contributor.authorRasmussen Busund, Lill-Tove
dc.date.accessioned2019-08-02T12:44:15Z
dc.date.available2019-08-02T12:44:15Z
dc.date.issued2019-01-23
dc.description.abstractA large number of miRNAs influence key cellular processes involved in prostate tumorigenesis. Previous studies have demonstrated high expression of miRNAs in human prostate cancer (PC) tissues and cell lines. In previous microarray data, we found miR-141 to be upregulated and miR-145 to be downregulated in PC. In this large PC cohort (n = 535), we explored the prognostic role of miR-141 and miR-145 in PC. Tumor epithelial (TE) and tumor stromal (TS) areas were evaluated separately and combined (TE + TS). <i>In situ</i> hybridization was used to evaluate the expression of the miRNAs. We found that miR-141 (TE) correlated significantly to Gleason score ≥8 (p = 0.040) and large tumor size (≥20 mm, p = 0.025) and miR-141 (TE + TS) to Gleason grade (p = 0.001). MiR-145 correlated to pT-stage (p = 0.038), tumor size (p = 0.025), Gleason grade (p = 0.051) and PSA (p = 0.032). In univariate analysis miR-141 (TE + TS) was significantly associated with biochemical failure-free survival (BFFS, p = 0.007) and clinical failure-free survival (CFFS, p = 0.021). For miR-145, there were no differences between patients with high versus low expression. In multivariate analysis overexpression of miR-141 in tumor epithelium and tumor stroma was significantly associated with BFFS (HR = 1.07 CI95% 1.00–1.14, p = 0.007). To conclude, high expression of miR-141 appears associated with increased risk of biochemical PC recurrence.en_US
dc.description.sponsorshipNorwegian Cancer Society (www.krefforeningen.no) The Northern Health Administration (www.helse-nord.no) UiT Arctic University of Norway (www.uit.no).en_US
dc.descriptionSource at <a href=https://doi.org/10.1038/s41598-018-36854-7>https://doi.org/10.1038/s41598-018-36854-7. </a>© The Author(s) 2019en_US
dc.identifier.citationRichardsen, E., Andersen, S., Melbø-Jørgensen, C., Rakaee, M., Ness, N., Al-Saad, S. ... Busund, L-T. (2019). MicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate cancer. <i>Scientific Reports</i>, 9:386. https://doi.org/10.1038/s41598-018-36854-7en_US
dc.identifier.cristinIDFRIDAID 1692066
dc.identifier.doi10.1038/s41598-018-36854-7
dc.identifier.issn2045-2322
dc.identifier.urihttps://hdl.handle.net/10037/15830
dc.language.isoengen_US
dc.publisherNature Researchen_US
dc.relation.journalScientific Reports
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710en_US
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710en_US
dc.titleMicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate canceren_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel